Bioxcel Therapeutics Inc (BTAI) said before open Tuesday that it lost $1.58 per share in quarter three 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.
On the revenue line, the company reported $341 thousand, missing estimates by $329 thousand.
In the same quarter a year ago, the company lost $1.49 per share on revenue of $137 thousand.
The stock is steady today at $3.68 after the report.
The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.
The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.
Trading in the five days leading up to the report earned Bioxcel Therapeutics Inc a Bullish Sentiment Rank from InvestorsObserver.
Prior to the report, InvestorsObserver gave the stock an overall score of 67. Meanwhile, the average Wall Street analyst rated the stock a Buy.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.
News Home
Bioxcel Therapeutics Inc Steady Today At $3.68 After Earnings Miss
Mentioned in this article
